‘The bar has risen’: China’s biotech gains push US companies to adapt

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder.

By Ben Fidler • Jan. 17, 2025

Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

There’s more to pharma's regulatory story in 2025 than just the IRA.

By Meagan Parrish • Jan. 17, 2025

Explore the Trendline➔

Tech for Clinical Trials

Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

By PharmaVoice staff

By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years

The J.P. Morgan Healthcare Conference has been a focal point for M&A year after year, and after a quiet period, the deals are back on the table.

By Michael Gibney • Jan. 16, 2025

Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?

A series of uncertainties that kept dealmaking to a minimum last year could be reversing as pharma reloads pipelines ahead of the patent cliff explosion.

By Michael Gibney • Jan. 14, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Coming changes that could impact pharma from drug development to launch.

By Meagan Parrish • Jan. 10, 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.

By Michael Gibney • Jan. 9, 2025

3 trial readouts that could shake up the obesity market this year

A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.

By Amy Baxter • Jan. 8, 2025

PharmaVoice’s Crystal Ball: The industry’s AI future

How AI will further transform the business of drug discovery and development in 2025.

By Meagan Parrish • Jan. 7, 2025

4 closely watched FDA approval dates in 2025 from J&J, Novo and more

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.

By Alexandra Pecci • Jan. 6, 2025

4 companies to watch in the accelerating gene editing race

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

By Kelly Bilodeau • Jan. 2, 2025

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

By Meagan Parrish • Dec. 20, 2024

A biotech’s race to tackle the most severe hepatitis

Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.

By Alexandra Pecci • Dec. 17, 2024

3 closely watched drugs that failed in the clinic

How recent setbacks and scattered successes could impact various sectors of the industry.

By Kelly Bilodeau • Dec. 16, 2024

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases. 

By Michael Gibney • Dec. 12, 2024

Endometriosis drug research, long underfunded, confronts familiar problems in women’s health

Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.

By Delilah Alvarado • Dec. 11, 2024

What’s next for 23andMe?

Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.

By Alexandra Pecci • Dec. 10, 2024

Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide

Leading companies in the psychedelics space have had trouble crossing the regulatory threshold. Here’s where they’re going wrong — and how to fix it.

By Kelly Bilodeau • Dec. 9, 2024

GSK taps a startup for shot at Alzheimer’s drug

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.

By Jacob Bell • Dec. 5, 2024

The big rebrand: Why these 4 biopharmas changed their name this year

Four companies that refreshed their mission and public persona with a new look.

By Alexandra Pecci • Dec. 4, 2024

How Alexion markets a rare disease drug by ‘starting with the end in mind’

The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.

By Michael Gibney • Dec. 3, 2024

Can the girl power of Arrivo’s depression drug help reverse its fortunes?

After failing a mid-stage trial, the biotech shifted course and is now targeting females with the goal of proving gender can play a role in depression outcomes.

By Kelly Bilodeau • Dec. 3, 2024

Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.

Intrinsic Medicine is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.

By Amy Baxter • Dec. 2, 2024

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.

By Michael Gibney • Nov. 26, 2024

What might a Trump administration mean for the Biosecure Act?

It’s still likely U.S. biotechs and pharmas will have to cut ties with key Chinese partners — it’s just a matter of when.  

By Amy Baxter • Nov. 20, 2024

The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.

The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.

By Alexandra Pecci • Nov. 19, 2024